Novus Therapeutics begins dosing in otitis media drug trial - Drug Development Technology

Novus Therapeutics begins dosing in otitis media drug trial  Drug Development Technology

Novus Therapeutics has commenced dosing in a Phase IIa trial of OP0201 for the treatment of otitis media, an inflammatory disease affecting the middle ear.



Comments

Popular posts from this blog

Summary of Society for Maternal-Fetal Medicine (SMFM) Consult Series #52: Diagnosis and management of fetal growth restriction - Contemporary Obgyn

Sarcoidosis: Causes, Symptoms, Diagnosis & Treatment